127 related articles for article (PubMed ID: 32080773)
1. Prognostic value of a 15-gene hypoxia classifier in oropharyngeal cancer treated with accelerated chemoradiotherapy.
Deschuymer S; Sørensen BS; Dok R; Laenen A; Hauben E; Overgaard J; Nuyts S
Strahlenther Onkol; 2020 Jun; 196(6):552-560. PubMed ID: 32080773
[TBL] [Abstract][Full Text] [Related]
2. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma.
Barney CL; Walston S; Zamora P; Healy EH; Nolan N; Diavolitsis VM; Neki A; Rupert R; Savvides P; Agrawal A; Old M; Ozer E; Carrau R; Kang S; Rocco J; Teknos T; Grecula JC; Wobb J; Mitchell D; Blakaj D; Bhatt AD
Oral Oncol; 2018 Apr; 79():9-14. PubMed ID: 29598954
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.
Rischin D; Young RJ; Fisher R; Fox SB; Le QT; Peters LJ; Solomon B; Choi J; O'Sullivan B; Kenny LM; McArthur GA
J Clin Oncol; 2010 Sep; 28(27):4142-8. PubMed ID: 20697079
[TBL] [Abstract][Full Text] [Related]
5. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE.
Suton P; Skelin M; Rakusic Z; Dokuzovic S; Luksic I
Eur Arch Otorhinolaryngol; 2019 May; 276(5):1275-1281. PubMed ID: 30887169
[TBL] [Abstract][Full Text] [Related]
7. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.
Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y
Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438
[TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal squamous cell carcinoma with low-neck or N3 disease.
Bhattasali O; Han J; Thompson LDR; Buchschacher GL; Abdalla IA; Iganej S
Oral Oncol; 2018 Mar; 78():151-155. PubMed ID: 29496043
[TBL] [Abstract][Full Text] [Related]
9. Combination of p16 levels and pre-radiotherapy factors predicts outcome in patients treated for oropharyngeal carcinoma.
Bar-Ad V; Wang ZX; Leiby B; Tuluc M
J BUON; 2013; 18(4):982-8. PubMed ID: 24344027
[TBL] [Abstract][Full Text] [Related]
10. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
[TBL] [Abstract][Full Text] [Related]
11. Detailed Analysis of Clinicopathologic Factors Demonstrate Distinct Difference in Outcome and Prognostic Factors Between Surgically Treated HPV-Positive and Negative Oropharyngeal Cancer.
Iyer NG; Dogan S; Palmer F; Rahmati R; Nixon IJ; Lee N; Patel SG; Shah JP; Ganly I
Ann Surg Oncol; 2015 Dec; 22(13):4411-21. PubMed ID: 25801358
[TBL] [Abstract][Full Text] [Related]
12. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
[TBL] [Abstract][Full Text] [Related]
13. Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial.
Bonner JA; Giralt J; Harari PM; Baselga J; Spencer S; Bell D; Raben D; Liu J; Schulten J; Ang KK; Rosenthal DI
Eur J Cancer; 2016 Sep; 64():1-11. PubMed ID: 27323346
[TBL] [Abstract][Full Text] [Related]
14. Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer.
Lassen P; Primdahl H; Johansen J; Kristensen CA; Andersen E; Andersen LJ; Evensen JF; Eriksen JG; Overgaard J;
Radiother Oncol; 2014 Dec; 113(3):310-6. PubMed ID: 25544647
[TBL] [Abstract][Full Text] [Related]
15. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
[TBL] [Abstract][Full Text] [Related]
16. T-category remains an important prognostic factor for oropharyngeal carcinoma in the era of human papillomavirus.
Mackenzie P; Pryor D; Burmeister E; Foote M; Panizza B; Burmeister B; Porceddu S
Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):643-7. PubMed ID: 25001635
[TBL] [Abstract][Full Text] [Related]
17. p16 Expression as a predictive biomarker of hypoxic cell-sensitizing agents in oropharyngeal cancer.
Chung CH; Raben D
J Clin Oncol; 2010 Sep; 28(27):4103-4. PubMed ID: 20697096
[No Abstract] [Full Text] [Related]
18. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck.
Toustrup K; Sørensen BS; Lassen P; Wiuf C; Alsner J; Overgaard J;
Radiother Oncol; 2012 Jan; 102(1):122-9. PubMed ID: 21996521
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.
Fakhry C; Zhang Q; Nguyen-Tan PF; Rosenthal D; El-Naggar A; Garden AS; Soulieres D; Trotti A; Avizonis V; Ridge JA; Harris J; Le QT; Gillison M
J Clin Oncol; 2014 Oct; 32(30):3365-73. PubMed ID: 24958820
[TBL] [Abstract][Full Text] [Related]
20. A quantitative histomorphometric classifier (QuHbIC) identifies aggressive versus indolent p16-positive oropharyngeal squamous cell carcinoma.
Lewis JS; Ali S; Luo J; Thorstad WL; Madabhushi A
Am J Surg Pathol; 2014 Jan; 38(1):128-37. PubMed ID: 24145650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
